CTTI Releases New Recommendations to Guide Use of Disease Progression Modeling in Medical Product Development

CTTI News | July 8, 2025

Topics Included: Innovative Trials, Regulatory Submissions + Approvals

CTTI today released new recommendations to support the effective use of disease progression modeling (DPM) in medical product development. The goal is to enable smarter, more efficient, and more evidence-based decisions by identifying when DPM should be considered and what is needed to implement it successfully. 

A disease progression model is a mathematical model that quantitatively describes the time course or trajectory of a disease. When used appropriately, DPM can integrate diverse sources of data—including translational, clinical, and real-world data—to improve trial design, reduce uncertainty, and tailor development strategies toward more personalized, targeted approaches. It can also help address knowledge gaps, support regulatory engagement, and strengthen the totality of evidence on a product’s benefit-risk profile. 

“DPM has tremendous potential to enhance decision making across the development lifecycle, particularly when having knowledge of the disease course is critical,” said Lindsay Kehoe, CTTI Senior Project Manager. “These recommendations are designed to help cross-functional leaders ask the right questions, appreciate the unique value of DPM, and apply it in ways that lead to better outcomes for patients.” 

Many decision makers in medical product development face uncertainty around when and how to apply DPM, and how to weigh its benefits alongside other modeling approaches. CTTI’s recommendations offer practical guidance to address these challenges and support more strategic, efficient decision making across clinical, regulatory, and translational functions. 

The recommendations were developed by experts from across the clinical trials ecosystem and further refined by a multi-stakeholder recommendations advisory group. 

More information on the Disease Progression Modeling project is available on CTTI’s website.

CTTI to Launch New Recommendations on Disease Progression Modeling in Free Public Webinar 

CTTI News | June 10, 2025

Topics Included: Innovative Trials

The Clinical Trials Transformation Initiative (CTTI) will host a free public webinar on Tuesday, July 8, to introduce new recommendations for using disease progression modeling (DPM) to improve medical product development. 

The webinar will include a welcome from Sara Calvert, CTTI director of projects; a keynote presentation from Cynthia J. (CJ) Musante, vice president of scientific research at Pfizer; a project overview from Lindsay Kehoe, CTTI senior project manager; and a panel discussion moderated by Kehoe featuring perspectives on the potential real-world application and impact of the recommendations. Panelists include Karthik Venkatakrishnan from EMD Serono, Tiffany Westrich-Robertson from AiArthritis, Theo Zanos from Northwell Health, and Efthymios Manolis from the European Medicines Agency. 

A disease progression model is a mathematical model that quantitatively describes the time course or trajectory of a disease. By integrating multi-disciplinary knowledge and data from different sources—including translational, clinical trial, and real-world data—DPM can improve trial design, answer questions of uncertainty, and support regulatory decisions. 

CTTI’s new recommendations aim to guide medical product development decision makers—such as clinical, regulatory, and innovation leaders—in identifying when DPM can offer unique value, what foundational elements are required, and how to communicate effectively with modeling experts to support its implementation. 

The 60-minute webinar will begin at 12:00 PM EDT. To attend, please take a moment to register 

We encourage you to share this announcement with colleagues or others in your network who may be interested in attending.

Collective Strategies to Enhance Proportionate Enrollment

Topics Included: Access to Clinical Trials, Patient Engagement, Recruitment, Regulatory Submissions + Approvals, Site Planning

The Collective Strategies to Enhance Proportionate Enrollment project focuses on improving accountability, clarity, and communication across clinical trials partner groups to support more effective recruitment, enrollment, and retention practices. This effort seeks to understand and address the challenges, expectations, and needs of each group involved in clinical trials, including contract research organizations, patient organizations, sites, and sponsors.

By fostering action-focused and unified engagement throughout the clinical trials process, the project aims to identify practical solutions that help plan, design, and execute trials better positioned to recruit and retain participants who reflect the epidemiology and scientific evidence of the disease under study. These efforts will support the generation of reliable, relevant, and robust data to inform the development of safe and effective medical products for all populations.

Key Takeaways

Resources

Regulatory Submissions + Approvals | CTTI News

CTTI Releases New Recommendations to Guide Use of Disease Progression Modeling in Medical Product Development

CTTI today released new recommendations to support the effective use of disease progression modeling (DPM) in medical product development.

Innovative Trials | CTTI News

CTTI to Launch New Recommendations on Disease Progression Modeling in Free Public Webinar

CTTI will host a free public webinar on Tuesday, July 8, to introduce new recommendations for using disease progression modeling (DPM) to improve medical product development.

Site Planning | CTTI News

CTTI Leads Discussion on Digital Health Trials at ETH Digital Biomarkers Summit

In November 2024, Lindsay Kehoe, senior project manager at CTTI, presented at the Digital Biomarkers Summit held at ETH Zurich.

Site Planning | CTTI News

New Publication Shares Findings & Recommendations for Embedding Clinical Trial Elements into Routine Clinical Practice

A new CTTI publication published in the Journal of Clinical and Translational Science highlights the qualitative research findings that informed recommendations to facilitate the integration of clinical trials into clinical practice.

Regulatory Submissions + Approvals | CTTI News

Recent CTTI Publication Reviews Current Applications and Future Opportunities for Disease Progression Modeling

A new CTTI publication, published in Clinical Pharmacology & Therapeutics, reviews current applications of disease progression modeling (DPM) and opportunities to advance the awareness and value of DPM in clinical...

Innovative Trials | Press Releases

New CTTI Recommendations Provide Path for More Efficient Clinical Trials Using Clinical Registries

Newly released recommendations from the Clinical Trials Transformation Initiative (CTTI) have the potential to streamline clinical trials by using registry information. Registries are data collection tools typically used to better...

Ensuring Quality | Press Releases

New Recommendations to Improve Quality in Clinical Trials

CTTI has issued recommendations and an associated toolkit to improve the quality and efficiency of clinical trials by helping sponsors to focus on study activities that are essential to the...

Patient Engagement | Press Releases

CTTI and FDA Convene Workshop on Including Patient Perspectives in Clinical Trials

The Clinical Trials Transformation Initiative (CTTI) will convene a public workshop, “Enhancing the Incorporation of Patient Perspectives in Clinical Trials," in collaboration with the U.S. Food and Drug Administration (FDA)...

Site Planning | Press Releases

CTTI Offers Path Forward for Using Decentralized Clinical Trials

The Clinical Trials Transformation Initiative (CTTI) will unveil new recommendations to speed the use of decentralized clinical trials (DCTs)—trials run through telemedicine and mobile health care providers—today at the DPharm:...

Formats

Stage of Trial

CTTI Leads Discussion on Digital Health Trials at ETH Digital Biomarkers Summit

CTTI News | November 27, 2024

Topics Included: Data Collecting and Reporting, Innovative Trials, Site Planning

In November 2024, Lindsay Kehoe, senior project manager at CTTI, presented at the Digital Biomarkers Summit held at ETH Zurich. The event gathered experts from academia, healthcare, and industry to discuss the transformative potential of wearable technologies in healthcare. Among the many topics covered, a key focus was the translation of digital innovations, such as wearable devices for sweat and breath, into clinical implementation to revolutionize healthcare. Digital technologies enable real-time, continuous monitoring of patient data, providing researchers and healthcare providers with deeper insights into patient health, improving trial design, and enhancing data accuracy.

In her workshop, Setting Up Digital Health Trials, Kehoe offered actionable insights on designing successful, fit-for-purpose digital health trials. She outlined key benefits, such as improving trial efficiency, fostering patient-centric research, and ensuring more reliable data. Kehoe also addressed common questions and challenges in implementing digital health trials and shared practical solutions for overcoming them. A central theme of her talk was the importance of communication and collaboration, emphasizing that “collaboration is key to bringing cutting-edge innovation into trials, addressing unmet needs, and improving trial efficiency.”

Dr. Jörg Goldhahn, a CTTI member and Professor at ETH Zurich, echoed Kehoe’s point, noting, “New technology offers great potential for novel biomarkers that can be used remotely, closer to ground truth, and on a continuous basis. However, intensive interprofessional collaboration is required to take these technologies from proof-of-concept into clinical use.”

Kehoe also discussed the importance of equipping researchers with the right tools and resources to successfully implement digital health strategies. She introduced essential resources from CTTI’s Digital Health Trials Hub, designed to guide researchers through key aspects of trial design, including selecting measures and appropriate technologies, managing data securely, developing novel endpoints, and collaborating effectively with clinical sites, patients, and regulators for seamless trial execution.

A notable example of how CTTI’s Digital Health Trials Recommendations are being put into practice is at ETH Zurich, where the institution has integrated these recommendations into its Digital Trial Intervention Platform within the Translational Science Advanced Studies program. This platform enhances the flexibility and scalability of clinical research and aims to optimize digital clinical study designs. These initiatives underscore the real-world impact of CTTI’s resources, demonstrating how we can take digital tools from bench to bedside and drive innovation in clinical research.

For those interested in seeing how CTTI’s resources are being applied in other research settings, the Case Study Exchange offers a range of real-world examples, showcasing how different organizations are integrating innovative tools and approaches into clinical trials.

New Publication Shares Findings & Recommendations for Embedding Clinical Trial Elements into Routine Clinical Practice

CTTI News | November 15, 2024

Topics Included: Data Collecting and Reporting, Innovative Trials, Site Planning

new CTTI publication published in the Journal of Clinical and Translational Science highlights the qualitative research findings that informed recommendations to facilitate the integration of clinical trials into clinical practice. By integrating key elements of clinical trials—such as patient identification and data collection—into everyday practice, research efforts can be streamlined to reduce duplication of activities. However, several administrative, cultural, and data-related challenges must be addressed to fully realize these benefits. 

The publication identifies barriers to embedding clinical trials into routine practice, including potential disruptions to workflow, challenges in obtaining buy-in from staff, the need for robust data and research infrastructure, and the necessity for a culture shift to value and support research. 

To address these barriers, recommendations are provided based on in-depth interviews and insights from two expert meetings hosted by CTTI. Key suggestions include ensuring healthcare data sources are research-ready, aligning trial designs with existing clinical workflows, preparing sites for trial integration, and securing support from leaders at regulatory, funding, and health system levels to champion the value of embedding trials in routine practice. 

Integrating trial elements into everyday clinical practice does not have to be an “all or none” approach. Even incorporating a few elements can bring significant benefits. By addressing the identified barriers and following these recommendations, long-term improvements in operational efficiency and patient outcomes can be achieved.

Recent CTTI Publication Reviews Current Applications and Future Opportunities for Disease Progression Modeling

CTTI News | October 17, 2024

Topics Included: Innovative Trials, Regulatory Submissions + Approvals

new CTTI publication, published in Clinical Pharmacology & Therapeutics, reviews current applications of disease progression modeling (DPM) and opportunities to advance the awareness and value of DPM in clinical trials. Use of modeling and simulation during drug development, otherwise known as model-informed drug development (MIDD), can help researchers make informed decisions when planning and executing clinical trials. DPM is one form of MIDD that integrates multiple types of data from various sources – including translational, clinical trial, and real-world data – to optimize trial design and execution and support regulatory decision-making. The potential of DPM has yet to be fully realized.  

To advance the use of disease progression modeling for decision making in clinical trials and medical product development, CTTI assembled a diverse project team, conducted a scoping literature review to identify current DPM applications, and shared these results at a multi-partner Expert Meeting with representatives from academia, data/tech organizations, government, the medical product industry, patients, and trade/professional organizations. They discussed the value of disease progression modeling and identified key areas that need to be addressed to incorporate DPM approaches more effectively in medical product development and regulatory decision-making. 

The paper presents the scoping review results, opportunities to increase uptake identified at the Expert Meeting, and proposes key questions that medical product developers and regulators may use to inform clinical development strategy and optimize trial design with disease progression models.

New CTTI Recommendations Provide Path for More Efficient Clinical Trials Using Clinical Registries

[yoast-breadcrumb]

CTTI Project: Registry Trials

Newly released recommendations from the Clinical Trials Transformation Initiative (CTTI) have the potential to streamline clinical trials by using registry information. Registries are data collection tools typically used to better understand long-term trends in a specific population, such as patients with a particular disease or patients exposed to a certain treatment.

PDF icon Download Press Release (194.86 KB)

CTTI and FDA Convene Workshop on Including Patient Perspectives in Clinical Trials

[yoast-breadcrumb]

CTTI Project: Patient Group Engagement

The Clinical Trials Transformation Initiative (CTTI) will convene a public workshop, “Enhancing the Incorporation of Patient Perspectives in Clinical Trials," in collaboration with the U.S. Food and Drug Administration (FDA) on Mon., March 18, from 9:00 a.m. to 5:00 p.m. at the Tommy Douglas Conference Center in Silver Spring, Md.

PDF icon Download Press Release (262.53 KB)